Cargando…
Proteasome inhibitor MG132 suppresses pancreatic ductal adenocarcinoma-cell migration by increasing ESE3 expression
The clinical significance of the proteasome inhibitor MG132 has been examined in numerous human cancer types; however, its influence on the metastasis and progression of pancreatic cancer is yet to be determined. In the present study, the effect of MG132 treatment on pancreatic ductal adenocarcinoma...
Autores principales: | Jin, Fanjie, Xiao, Di, Zhao, Tiansuo, Yu, Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924158/ https://www.ncbi.nlm.nih.gov/pubmed/31897200 http://dx.doi.org/10.3892/ol.2019.11157 |
Ejemplares similares
-
The proteasomal inhibitor MG132 prevents muscular dystrophy in zebrafish
por: Winder, Steve J, et al.
Publicado: (2011) -
Proteasome inhibitor MG-132 induces MCPIP1 expression
por: Skalniak, Lukasz, et al.
Publicado: (2013) -
Effects of proteasome inhibitor MG-132 on the parasite Schistosoma mansoni
por: Morais, Enyara R., et al.
Publicado: (2017) -
ESE3-positive PSCs drive pancreatic cancer fibrosis, chemoresistance and poor prognosis via tumour–stromal IL-1β/NF–κB/ESE3 signalling axis
por: Zhao, Tiansuo, et al.
Publicado: (2022) -
Systemic Perturbation of the ERK Signaling Pathway by the Proteasome Inhibitor, MG132
por: Cirit, Murat, et al.
Publicado: (2012)